Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 16/20 | 0.55 |
| ▸ | AKT2 | P31751 | 1/20 | 0.55 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 15/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 12/20 | 0.51 |
| ▸ | INCENP | Q9NQS7 | 11/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10093522 | 0.92 | AKT1 (0.61) | AKT1AKT2AKT3RPS6KB1AURKB | |
| SCHEMBL17200075 | 0.91 | AKT1 (0.62) | AKT1AKT2AKT3RPS6KB1AURKB | |
| SCHEMBL17200061 | 0.91 | AKT1 (0.61) | AKT1AKT2AKT3RPS6KB1AURKB | |
| SCHEMBL17200084 | 0.89 | AKT1 (0.56) | AKT1AKT2AKT3RPS6KB1AURKB | |
| SCHEMBL17200073 | 0.88 | RPS6KB1 (0.61) | AKT1RPS6KB1AURKBINCENPAURKA | |
| SCHEMBL17200080 | 0.86 | RPS6KB1 (0.62) | AKT1AKT2AKT3RPS6KB1AURKB | |
| SCHEMBL10093514 | 0.85 | RPS6KB1 (0.72) | AKT1RPS6KB1AURKBINCENPAURKA | |
| SCHEMBL14983863 | 0.85 | RPS6KB1 (0.72) | AKT1RPS6KB1AURKBINCENPAURKA | |
| SCHEMBL17200107 | 0.84 | AKT1 (0.49) | AKT1AKT2AKT3RPS6KB1AURKB | |
| SCHEMBL10093519 | 0.83 | RPS6KB1 (0.74) | AKT1RPS6KB1AURKBINCENPAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598492-B1 | BICYCLIC AZAHETEROCYCLIC CARBOXAMIDES AS INHIBITORS OF THE KINASE P70S6K | MERCK PATENT GMBH (DE) | 2015-10-28 | — | — | EP | disclosed |